Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT03399799)
64407564MMY1001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \[Dose Escalation\]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part 2 \[Dose Expansion\]).
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of Alabama Birmingham — Birmingham, Alabama
- City of Hope — Duarte, California
- University of Colorado Cancer Center — Aurora, Colorado
- Mount Sinai Medical Center — New York, New York
- Tennessee Oncology — Nashville, Tennessee
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman — Liège,
- VU Medisch Centrum — Amsterdam,
- UMCU — Utrecht,
- Hosp. Univ. Germans Trias I Pujol — Badalona,
- Hosp Univ Fund Jimenez Diaz — Madrid,
- Clinica Univ. de Navarra — Pamplona,
- Hosp. Quiron Madrid Pozuelo — Pozuelo de Alarcón,
- Hosp Clinico Univ de Salamanca — Salamanca,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematological Malignancies
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
- Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies — Houston, Texas
- Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
- Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies — Houston, Texas
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Hematological Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.